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Abstract:  Next-generation sequencing technologies have afforded unprecedented characterization of 
low-frequency and rare genetic variation.  Due to low power for single-variant testing, aggregative 
methods are commonly used to combine observed rare variation within a single gene.  Causal 
variation may also aggregate across multiple genes within relevant biomolecular pathways.  Kernel-
machine regression and adaptive testing methods for aggregative rare-variant association testing have 
been demonstrated to be powerful approaches for pathway-level analysis, although these methods 
tend to be computationally intensive at high-variant dimensionality and require access to complete 
data.  An additional analytical issue in scans of large pathway definition sets is multiple testing 
correction.  Gene-set definitions may exhibit substantial genic overlap, and the impact of the resultant 
correlation in test statistics on Type I error rate control for large agnostic gene-set scans has not been 
fully explored.  Herein, we first outline a statistical strategy for aggregative rare-variant analysis using 
component gene-level linear kernel score test summary statistics as well as derive simple estimators 
of the effective number of tests for family-wise error rate control.  We then conduct extensive 
simulation studies to characterize the behavior of our approach relative to direct application of kernel 
and adaptive methods under a variety of conditions.  We also apply our method to two case-control 
studies respectively evaluating rare variation in hereditary prostate cancer and schizophrenia.  Finally, 
we provide open-source R code for public use to facilitate easy application of our methods to existing 
rare-variant analysis results. 
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INTRODUCTION 
Next-generation sequencing (NGS) is rapidly emerging as a primary technology for evaluating the 
role of genetic variation in human phenotypes.  Unlike the standardized genotyping arrays used in 
genome-wide association studies, which interrogate tagging single nucleotide polymorphisms (SNPs) 
to indirectly capture the majority of common variation (i.e., minor allele frequency (MAF) > 5%) via 
linkage disequilibrium, NGS studies provide nucleotide-resolution information of the targeted DNA 
through massively parallel short-read sequencing, capable of directly identifying causal variation.  
This is a critical advantage with the recent interest in the role of rare genetic variation in complex 
traits.  Many arguments exist that not only support this model of genetic association from a population 
genetics perspective[1], due to a rapidly increasing population size and weak purifying selection, but 
suggest that rare variation may constitute a large portion of the so-called missing heritability observed 
in many complex traits[2, 3]. There is now a growing list of examples where high-impact rare variants 
have been identified in complex diseases[4, 5]. 
Although sequencing costs continue to decline as technology improves, NGS studies still 
remain quite expensive and sample sizes are often too small to be sufficiently powered for gene-based 
aggregative rare-variant testing[6].  However, aggregative gene-set analyses informed by molecular 
pathways and/or perturbation studies may be sufficiently powered by combining genetic variation 
across functionally related genes.  Moreover, they may capture genetic heterogeneity of etiological 
mechanisms at a larger systematic level, as these complex traits are likely multi-factorial and could be 
driven by the disruption of one of any number of key genes in a particular molecular pathway.  
Analyses involving aggregation of rare variants across large gene-sets have recently been applied in 
studies of non-obstructive azoospermia[7], adolescent idiopathic scoliosis[8], and schizophrenia[9]. 
Various extensions of rare-variant testing to the pathway level using self-contained testing 
have previously been explored[6].  Yan et al. recently proposed adaptive rank-truncation product 
(ARTP) methods in conjunction with kernel-machine regression testing[10], which demonstrated 
statistical power improvements over direct application of the popular sequence kernel association test 
(SKAT)[11].  However, these approaches are permutation-based and consequently computationally 
demanding, with moderately sized (80-100 genes) gene-sets requiring thousands of minutes of 
compute time.  Pan et al.[12] extended their adaptive score power test (aSPU) to genetic pathways 
(aSPUpath), which is also based upon score tests and applicable to common and rare variation, with 
permutation or parametric bootstrap applied to obtain gene-set p-values.  While these adaptive 
methods have demonstrated advantages in statistical power over competing approaches, their 
implementation requires access to the complete datasets to conduct gene-set testing, limiting their 
application.   
Evaluation of Type I error rate control for gene-set analysis is also understudied.  In contrast 
to gene-based rare-variant tests, which can justifiably be assumed to be independent due to anticipated 
low linkage disequilibrium amongst rare variation, multiple testing correction for gene-set aggregative 
testing is complicated by the potential for substantial genic overlap.  Examination of the latest version 
(v5.1) of the C2 curated gene-set collection present in the Molecular Signatures Database[13, 14] 
(MSigDB, http://software.broadinstitute.org/gsea/msigdb) reveals 4726 total gene-sets, in addition to 
the 1454 Gene Ontology[15] (GO) gene-sets.  A total of 13,311 gene-sets encompass the entire 
available list.  An agnostic scan of all available gene-sets could result in thousands of correlated test 
statistics, for which traditional multiple testing correction methods (e.g., Bonferroni) may be overly 
conservative without acknowledging this correlation structure.   
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Wu et al.’s examination of rare-variant pathway analysis strategies identified the direct 
application of SKAT to the union of rare-variant genotypes across the gene-set (i.e., “super gene” 
approach) to perform well across a variety of conditions[6].  An advantage of this approach is that 
linear kernels can easily be combined to form composite kernels, supporting the hierarchical 
framework for gene-set kernel construction.  Herein, we first outline a computationally efficient 
strategy for conducting gene-set based rare-variant association analyses and evaluate estimators of the 
effective number of gene-set tests based on SKAT and its burden/kernel optimized variation, SKAT-
O[16].  We then conduct simulation studies under null conditions to characterize the properties of our 
gene-level p-value aggregation approach relative to direct application of kernel-based tests as well as 
demonstrate proper control of the family-wise error rate (FWER) for simultaneous analysis of large 
numbers of overlapping gene-sets.  We also investigate comparative power relative to approaches 
using complete data as well as any practical impacts on study design when proper FWER control is 
implemented relative to conservative Bonferroni adjustment.  Finally, we apply our approach to a 
case-control sequencing study of hereditary prostate cancer and previously published results from a 
case-control study of schizophrenia using exome chip array data. 
METHODS 
Kernel-Machine Association Testing for Rare Variants 
Consider a rare-variant association study of sample size   with a given     phenotype vector  , 
such that genotype dosages are available on   subjects for   genes.  Let  ̂ correspond to a vector of 
fitted phenotype values (if   is continuous) or trait probabilities (if   is dichotomous) from a relevant 
regression model taking into account adjusting covariates (e.g., age and sex).  Hypothesis testing for 
gene-level rare-variant association analysis may be conducted using an aggregative variance 
component testing approach, like SKAT, such that a kernel test score statistic for a given gene 
        is defined as    (   ̂)
 
  (   ̂), where   is a kernel representation of   variants 
within the tested region(s) of gene  .  For a weighted linear kernel function, we explicitly define   to 
be represented as         , where   is an     matrix of variant genotypes and   is an 
      diagonal weight matrix.  The test statistic    then follows a mixture chi-square distribution 
under the null hypothesis. 
Extension to Gene-Set Analyses 
Define the set   *     + to represent a given gene-set or pathway, such that it is defined by the 
subset of     total genes.  A gene-set test statistic may be defined similarly to that conducted at the 
gene-level, whereby    is an     composite matrix formed by appending the genotype matrices 
of the   component genes that comprise  , given as (       ).  Then, we define the gene-set 
test statistic    (   ̂)
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Thus,   is a linear composite kernel matrix of the component gene-level kernel matrices, and 
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(∑      )(   ̂)  ∑      .  For rare variation, it is reasonable to assume that the 
gene-level score statistics *      + are independent, so long as the variant sets are non-overlapping.  
Under these conditions, a simple solution to deriving gene-set level test p-values is to combine pre-
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computed gene-level p-values,   , using p-value aggregation approach, such as Fisher’s method[17] or 
Stouffer’s combined Z-score[18].  We elect the latter, as it affords working with multivariate 
normality and gene-based weights, if warranted, are easily supported.  Moreover, Stouffer’s method 
tends to be more powerful than Fisher’s when a large proportion of testing results are moderately 
significant[19], which may more likely reflect the underlying biology in pathway-directed analysis.  
Define     
  (    ) where 
  ( ) is the inverse cumulative density function (CDF) of the 
standard Gaussian distribution, such that under the null condition     (   ), For a given gene-set   
with   genes,    
∑      
√ 
 and    also follows a standard Gaussian distribution under the gene-set null 
condition, from which a gene-set p-value can be easily computed.  Note that in addition to SKAT, 
these results also generalize to SKAT-O[16], as   can simply be substituted by  
   ((    )  
    
 )  
    with the caveat that    is pre-selected gene-wise rather than optimized over the entire set 
of variants   .  We refer to this approach generally as gsSKAT. 
Multiple Testing Correction 
When testing a large number of gene-sets,  , such as via an agnostic scan of multiple curated gene-
sets (e.g., GO), significance threshold adjustment such as a Bonferroni correction is very likely to be 
overly conservative due to substantial overlap of genes across gene-sets.  Consider a second gene-set 
   with    genes such that         .  The covariance    (      ) may be derived using the 
bilinearity of covariance, such that 
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where |    | corresponds to the cardinality of the intersection of   and   , equivalent to the number 
of overlapping genes.  More generally, we derive the correlation matrix of the pathway-level Z-scores 
by defining a     pathway design matrix, , for   unique pathways, such that matrix element 
    
 
√  
 if gene   is in   , where    is the total number of genes in pathway  , and 0 otherwise.  Then, 
     (   ) where      .  We consider estimates of the effective number of tests via the 
Galwey method[20] and the modification of the Gao approach described by Hendricks et al.[21]  Let 
  be the vector of eigenvalues corresponding to the eigendecomposition of  .  A Galwey estimate for 
the effective number of gene-set level tests,        
   , is given by        
    
(∑√  )
 
∑  
 for     , where 
   indicates the  
   largest eigenvalue.  For the Gao estimator,     
    is equivalent to the smallest    
that satisfies 
∑ |  |
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  , where   is set to the recommended value of 0.995.  Estimates of      may 
in turn be applied as a Bonferroni correction factor for adjusting the statistical significance threshold 
to maintain proper FWER control.  Despite the potentially large dimensionality of   , efficient 
computation of   can easily be conducted by exploiting sparse matrix algebra. 
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Simulation Study 
To simulate genotypes under realistic rare-variant distributions and frequencies, empirical MAF data 
were downloaded from the NHLBI-ESP Exome Variant Server (release ESP6500).  We isolated the 
European American MAFs for all observed polymorphic sites, and all variants with MAF >0.05 were 
excluded as common SNPs.  To simulate genotype data for genes that would likely pass traditional 
gene-level rare-variant testing criteria (e.g., sufficient number of minor alleles and variant positions), 
we first identified the subset of genes with a cumulative MAF (cMAF) > 0.01 and total number of 
variant positions between 10 and 100.   We then randomly sampled ten gene-sets corresponding to 
181 unique genes from the Reactome[22] pathway database ranging in gene-set size from 6 to 47 as 
well as varying degrees of overlap (Table I).    
To characterize the p-value aggregative approach under a variety of study conditions, we simulated 
rare-variant genotypes for the 181 genes for an underlying population of 20,000 samples.  Genotypes 
were simulated independently across samples and variant sites under assumptions of Hardy-Weinberg 
equilibrium.  We employed a similar simulation strategy for phenotypes as defined in Wu et al.[11], 
such that we defined continuous outcome    independently as 
                     
      
where      (   ),              (   ), and     (   ) were all independently sampled for each 
simulated subject.  For power simulations, we defined causal genetic effects   (       )
  for  
total gene-set variants such that |  |      |      (    )| if the variant  was designated to be 
causal and 0 otherwise, where     is the population MAF of the 
   variant.  For binary traits with 
trait probability   , we modeled      (  ) the same as continuous outcome   , with the exception that 
we additionally included an intercept    such that disease prevalence was approximately 10%. 
Type I Error and FWER  
To characterize the behavior of gsSKAT under null conditions, we considered total sequencing study 
sample sizes of N = 1000 and 2000, which were randomly drawn from the larger population of 20,000 
samples with replacement for each simulation iteration.  SKAT and SKAT-O kernel testing was 
conducted for all individual genes as well as the 10 gene-sets under all simulation conditions, while 
Stouffer’s combined p-values were also computed for the gene-sets based on the component gene-
level p-values.  Finally, SKAT-O has a tendency to produce p-values of 1.00, which would yield 
negative infinity values from    ( ).  In the event of       , we set        to avoid this issue.  
For these simulations, 5000 iterations were conducted per analysis. 
To evaluate proper control of the FWER rates for a given   using the adjusted multiple 
testing correction factor     , we additionally simulated uniformly distributed p-values for 19,399 
genes present in the ESP6500 dataset as the basis for gene-set analysis.  We considered three separate 
magnitudes of analyses defined by the total number of gene-sets under consideration, denoted   ,   , 
  , that were respectively comprised of all gene-sets with   | |       in Reactome (673 gene-
sets), Reactome and GO (2109 total gene-sets), and MSigDB C2 and GO (6124 total gene-sets).  We 
presumed that these analyses would be typical of most agnostic gene-set scans conducted by an 
investigator.  For each analysis, we enumerated the number of instances a Type I error occurred at an 
adjusted  -level of 0.05 using each of the two      estimates as a Bonferroni correction factor.  A 
total of 10,000 replications were conducted for each analysis. 
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Statistical Power 
There are myriad configurations of genetic architectures (e.g., causal variant proportion, direction of 
effects, relationship between effect magnitude and MAF) under which statistical power may be 
calculated for aggregate rare-variant testing methods.  To investigate relative statistical power of our 
p-value aggregation method compared to direct applications of competing approaches using available 
genetic, covariate, and phenotypic data, we conducted a variety of simulations based on continuous 
(      ) and dichotomous (      ) outcomes for a limited set of realistic conditions using 
data for gene-sets (               ).  We defined the genetic architecture of a causal genetic pathway 
hierarchically, such that a gene-set is comprised of causal and null genes, and causal genes are 
comprised of causal and null variants.  For our purposes, we randomly selected approximately 5% of 
the variants to be causal for a given causal gene for continuous outcomes and 10% for binary in order 
to achieve adequate power, and considered causal gene proportions across the gene-set to be 100%, 
~50%, and ~25%.  Finally, we considered effects to be either all positive or a randomly selected 
mixture of positive and negative.  Genetic profiles were randomly selected from the population of 
20,000 previously generated genotype vectors, while a larger population of 50,000 subjects was 
generated for binary outcomes by sampling with replacement.  In addition to SKAT-O and gsSKAT 
using gene-level SKAT-O p-values, we also applied the aSPUpath adaptive test using the aSPU R 
package.  The aSPUpath test was applied using 10,000 permutations, with all other settings set to 
defaults.  A total of 1000 simulation iterations were performed per analysis, and all testing results 
were considered significant at an   level of 0.05. 
Quantifying potential improvements in power via correct selection of an adjusted   level is 
another statistical power consideration of direct relevance to this work.  To evaluate the practical 
impact of proper FWER control using      relative to a conservative Bonferroni adjustment on 
power, we estimated statistical power for an example gene-set,   , as part of a hypothetical agnostic 
scan of a gene-set associations for each of the three gene-set analyses (  ,   ,   ) described above.  
Specifically, power was estimated at Bonferroni-corrected   levels of 0.05 where the correction factor 
was set as either   or     .  We applied the built-in power calculation functions in the SKAT R 
package to calculate power estimates under specific   levels under a causal variant percentage of 
0.10, causal variant MAF threshold of 0.05, and even mixture of positive and negative effects, with all 
other settings set to default parameters.   We calculated statistical power for continuous and 
dichotomous outcomes for samples sizes of (500,1000) and (2000,4000), respectively, as well as the 
minimum sample size necessary to achieve 80% power under both adjusted significance thresholds, 
based upon simulated haplotype data for variants included in   . 
Application:  Prostate Cancer Risk 
We first applied our gsSKAT approach to 333 cases and 349 controls using data from a whole-exome 
sequencing (WES) case-control study of hereditary prostate cancer (PRCA) conducted by the 
International Consortium of Prostate Cancer Genetics (ICPCG), previously detailed elsewhere[23].  
Briefly, WES was performed using the Agilent 50Mb SureSelect Human All Exon chip or the Agilent 
SureSelect V4+UTR kit.  Eligible variants for association testing were then identified as 
corresponding to MAF < 0.05 and corresponding to functional status of nonsense, missense, or splice 
site variation.  SKAT-O was then applied at a gene-level to all genes with   eligible variant 
position, adjusting for capture kit (dichotomous) and the first five principal components derived from 
the complete genotype data.  Variant weighting was defined by functional impact, such that nonsense 
and splice-site variants received weights of 1.0 and missense variants were weighted using random 
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forest classification trees built using 15 features from dbNSFP, including seven functional prediction 
scores.  Additional processing details are presented in the Supplemental Information.  We considered 
all gene-sets with set size between 5 and 1000 genes within the curated pathways (CP) subset of the 
MSigDB C2 list, which includes 1330 gene-set definitions from Reactome, KEGG[24], PID[25], and 
other online gene-set databases, along with gene-sets from GO. 
Application:  Schizophrenia 
A primary advantage of gsSKAT is that it can easily be applied to previously published gene-level 
rare-variant analysis results.  Recently, Richards et al.[9] conducted a large case-control study of 
schizophrenia using the Illumina (San Diego, CA) HumanExome Array on 8103 controls and 5585 
cases from the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) [26].  
Notably, the authors had applied SKAT-O at both a gene and gene-set level, with complete results 
from the former reported as supplemental material.  For purposes of comparison and to explore the 
utility of applying gsSKAT to pre-existing results of other studies, we applied gsSKAT to the reported 
SKAT-O p-values from Richards et al. using the same settings selected for the PRCA analysis. 
RESULTS 
Gene-Set P-values 
Gene-set p-values derived from direct application of SKAT on    demonstrated high correlation with 
those computed using the Stouffer combined Z approach, with Spearman correlation coefficients 
ranging from 0.84 to 0.92.  Results were comparable across gene-set size, sample size, and outcome 
type.  In contrast, the results for SKAT-O, while still highly correlated, demonstrated a sizable 
reduction in rank correlation between the directly computed and Stouffer combined results (Figure 1).  
The degree of correlation also reduced with the gene-set size, with rank correlations for    (6 genes) 
ranging from 0.59 to 0.62, while those for     (47 genes) ranged from 0.45 to 0.50.  This is not 
altogether surprising, since as we previously noted, the correlation parameter    in SKAT-O is 
estimated independently for each component gene in the gene-set prior to p-value aggregation, thus 
resulting in a different underlying hypothesis.  Moreover, it is expected that the correlation between 
direct application of SKAT-O and aggregation of gene-level SKAT-O p-values would degrade as the 
number of genes increases. 
Type I Error Rate 
Table II presents the empirical false positive rates (FPRs) for each of the 10 example Reactome gene-
sets across the various conditions in our simulation study.  Overall, direct application of SKAT or 
SKAT-O to the aggregated genotype data tended to be conservative, with binomial testing relative to 
the expected FPR at an   level of 0.05 resulting in significant (  
    
   
       ) deviation for 
multiple simulation scenarios.  This degree of conservative bias demonstrated a trend with gene-set 
size, with larger gene-sets trending to more conservative results.  The conservative bias also appeared 
to be more prevalent and severe for continuous rather than binary outcomes.  In contrast, the 
Stouffer’s combined Z p-values from gsSKAT were largely within expectation under the null, with 
one instance of a simulation condition resulting in significantly inflated type I errors (    for a binary 
outcome using SKAT and N = 2000:  FPR = 0.0632).   
Multiple Testing Correction 
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For the three separate gene-set lists, estimates of the effective number of tests were approximately 
half the quantity of respective gene-sets themselves using        
   , while     
    ranged between 72% 
and 81% of the total number of gene-sets  (Table III).  With respect to FWER control using   and 
the two effective test number estimates, binomial testing indicated significantly (  
    
 
       ) 
conservative FWER control using   as a Bonferroni correction factor but significantly liberal results 
for        
   .  In contrast, use of     
    resulted in FWER estimates that were approximately equal to 
the assumed testing size, regardless of which list of gene-sets was applied. 
Power 
Complete simulation results for all gene-sets under similar are presented in Table IV.  Overall, we 
observed a trend of a reduction in power for the gsSKAT analysis of gene-level p-values relative to 
methods using complete data, with differentials as high as 15-20% in isolated instances.  This was 
observed notably for continuous outcomes under simulation scenarios where gene-sets were 
comprised of relatively few genes and causal variant effects that were in the same direction, while 
differences in power for binary outcomes tended to be less pronounced.  For larger gene-sets with a 
mixture of effect directions, the gsSKAT approach using SKAT-O p-values was competitive even 
with aSPUpath, especially for binary outcomes when the proportion of causal genes was lower.  
Given that median gene-set size for pathway collections defined by      , and    ranged from 26-34 
genes, results for gene-sets   ,     and    are likely most relevant for broad characterization of 
relative power.  Although the adaptive approach aSPUpath did not demonstrate substantially strong 
power advantages over the SKAT kernel-regression methods as previously reported, it is important to 
note that our simulation conditions supported the default variant weighting assumptions of SKAT-O 
by establishing a negative correlation between effect size and MAF.   
In general, selection of      (based upon the Gao approach) versus   as a Bonferroni 
correction factor yielded minimal advantages in statistical power over the various study conditions 
(Table V), with realized gains in power ranging from 0.009 to 0.017.  Similarly, the minimum sample 
sizes to achieve 80% power using the      correction factor resulted in 0.8-2.5% decrease in number 
of necessary samples across the simulations.  Results were comparable across the nature of the 
phenotype (binary or continuous) and exhibited reduced benefit as sample size increased.  Results for 
other example gene-sets and simulation conditions produced similar results (data not shown). 
Data Applications 
Gene-set analyses for both PRCA and schizophrenia respectively returned one and two significant 
findings (Figure 3).  For PRCA, the GO gene-set Regulation of Apoptosis (GO:0042981), which 
interestingly would not have been declared significant by standard Bonferonni adjustment, consisted 
of 305 genes with observed genetic variation out of 341 total genes.  A Manhattan-style plot of the 
component gene-level p-values is presented in Figure S1, with FASTK (P = 8.6E-05) corresponding to 
the most significant result.   The two significant results from the schizophrenia analysis were also GO 
gene-sets, Membrane Lipid Biosynthetic Process (GO:0046467) and Lipid Biosynthetic Process 
(GO:0008610), the former nested within the latter.  For GO:0046467, a total of 13/35 genes 
corresponded to a p-value < 0.1.  Comparisons between the subset of reported gene-sets by Richards 
et al. that overlap with our results are reported in Table S2.  
Computational Efficiency 
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Conditional on the availability of pre-computed gene-level p-values, computational timing for 
computing the gene-set p-values and deriving      is largely trivial.  The average analysis time for 
the FWER simulations per replication of the    scale analysis was approximately 170 seconds on a 
desktop computer with an Intel® Core™ i5-6500 processor and 8 GB of RAM.  Computing gene-set 
p-values from gene-level results also precludes the need to apply SKAT to potentially high-
dimensional genotype matrices under large  , as these analyses may incur hours of compute time 
per gene-set when       . 
DISCUSSION 
As sequencing costs diminish and the number of published rare-variant association studies continues 
to grow, secondary analysis of gene-level testing results may identify significant aggregation of rare-
variant associations in relevant biological pathways.  Herein, we have outlined a simple and effective 
strategy for conducting large-scale gene-set analyses using gene-level kernel testing results while 
simultaneously investigating multiple testing correction and correlated test statistics due to genic 
overlap.  From our simulations, we found p-value aggregation using Stouffer’s combined Z method to 
be highly correlated with results corresponding to direct application of kernel-machine testing across a 
wide variety of conditions, particularly for SKAT.  These methods also demonstrated proper test size 
across various sizes of gene-sets.  Results were expectedly less correlated for SKAT-O, for which the 
parameter that determines the optimal combination of burden and kernel testing is estimated per gene 
rather than across the entirely of the gene-set.  This distinction is subtle yet clearly relevant to the end 
result of the hypothesis test.  Accommodating gene-level control of this parameter is equivalent to 
allowing the distribution of variant weight parameters to vary by gene with respect to distribution of 
effect directionality and causal status, which may have biological justification. 
Our simulation results indicated that, while proper control of Type I errors is preserved in our 
gsSKAT p-value aggregation testing strategy, a moderate degree of statistical power may be lost 
relative to direct application of leading gene-set testing methods on the raw data.  Consequently, ideal 
analysis conditions would involve access to all genetic, covariate, and phenotype information to apply 
methods such as aSPUpath.  However, gsSKAT did perform competitively for gene-sets that are 
typical of large pathway definition sets such as KEGG or Reactome, and may also prove useful as a 
complementary analytical approach for sizable gene-sets that present computational issues for kernel 
testing.  Additionally, the major advantage of our approach is that it can easily be applied to existing 
sequencing studies for which gene-level p-values are readily available.  Given the growing number of 
sequencing studies and wide-scale adoption of kernel testing for gene-level rare-variant testing, 
gsSKAT provides an efficient approach for hypothesis generation using simple summary statistics 
from prior studies.   
Our results also suggest that the practical implications of proper estimation of the effective 
number of tests for large agnostic scans of available gene-sets appear largely inconsequential.  
Although strict Bonferroni adjustment resulted in significantly conservative control of the FWER, the 
degree of this deviation was relatively marginal.  As demonstrated by our proposed typical analyses of 
up to 6124 gene-sets, the effective number of tests tends to be approximately 70-80% of the total 
gene-set count, based upon the Gao estimator of     .  However, targeted analyses of relatively few 
highly-overlapping gene-sets may induce a stronger correlation structure.  Consequently, estimation 
of      may be useful on a case-by-case basis to evaluate the test statistic correlation structure for a 
given analysis when designing a pathway-centric sequencing study. 
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We applied gsSKAT to two different case-control studies of rare variation:  the ICPCG case-
control WES study of hereditary PRCA as well as a previously published large case-control study of 
schizophrenia using exome chip data by the PGC.  For the former, we identified one significant result, 
the GO gene-set GO:0042981, which encompasses 341 genes that modulate the occurrence and/or 
rate of apoptotic processes.  Programmed cell death is a fundamental mechanism of tumor 
suppression, and genetic damage of apoptotic pathways is a key stage in tumorigenesis[27].  Although 
the scale of this finding in regards to number of genes renders interpretation relatively difficult, 
follow-up custom-capture sequencing of the gene-set members in a replication cohort could assist in 
resolving what elements of apoptotic pathways are relevant to hereditary PRCA.  
The schizophrenia analysis results from gsSKAT are unexpected in that Richards et al.[9] also 
conducted exploratory gene-set analyses on these data, albeit by directly applying SKAT-O to the 
complete variant sets.  However, neither of the two hits we identified were among the subset of 
moderately associated (P<0.01) gene-sets reported by Richards et al., despite their inclusion in the 
afore-mentioned analyses.  Although the correlation between direct SKAT-O results and those 
obtained via gene-level p-value aggregation is markedly reduced in comparison to SKAT, it is 
nonetheless surprising to observe such a disparity.  The gene-set in question is the GO set 
GO:0046467, a biological process gene-set corresponding to reactions or molecular pathways 
involved in the formation of membrane lipids.  There is a large body of literature indicating 
membrane lipids play a role in the development of schizophrenia[28-30].  Recently, Steen et al.[31] 
also published research implicating SREBP-mediated lipid biosynthesis via genetic variation in 
transcription factor genes SREBF1 and SREBF2 in the development of schizophrenia.  The top gene-
level result within this pathway was phosphatidylinositol glycan anchor biosynthesis class G (PIGG:  
P = 1.8E-04), which belongs to a class of genes involved in glycosylphosphatidylinositol biosynthesis.  
Pathogenic genetic variation in PIGG was recently identified to cause intellectual disability with 
hypotonia[32]. Interestingly, multiple PIG genes were also recently identified to overlap copy number 
variations associated with schizophrenia[33] 
 A notable shortcoming of our strategy is that it necessitates the use of linear kernel functions 
in the kernel-based score testing to satisfy the underlying assumptions.  Extensions to non-linear 
kernel functions, such as the Gaussian kernel, are limited by the inability to decompose the composite 
gene-set kernel matrix into a linear combination of gene-level component kernels.  Consequently, not 
only must    be explicitly computed from the complete data, but deriving the covariance structure of 
gene-set statistics requires much more rigor.  However, this could still be obtained relatively 
efficiently using parallel computing and/or trace inequalities.  Extending meta-analytic strategies for 
SKAT[34] to aggregate results not only across genes in gene-sets but also across different studies is 
another research avenue of interest.  Finally, we would recommend to investigators with access to 
complete data to adopt previously mentioned adaptive approaches for rare-variant gene-set analyses, 
such as SKAT-ARTP[10] or aSPUpath[12], as the corresponding improvements in statistical power 
reported by the authors likely justify the computational costs.  Additionally, permutation schemes that 
adapt to the estimated null tail probability can render these approaches feasible for larger agnostic 
scans, although careful consideration is necessary for sufficient permutations to appropriately control 
the Type I error rate under high multiple testing dimensionality[35].  We have conveniently provided 
an R implementation for the above-described methods with code available in the appendix.  We have 
also currently built in support for the Gene Matrix Transposed (GMT) file format to easily import 
gene-set definitions and readily enable rare-variant gene-set scans of popular curated gene-sets 
available on the MSigDB website. 
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As our understanding of molecular pathways and their modularity continues to improve, 
leveraging curated gene-sets may improve rare-variant association studies of complex traits where 
genetic heterogeneity is plausible.  Our work demonstrates that applying p-value aggregation methods 
to gene-level kernel testing results can be an effective strategy for large-scale evaluation of gene-sets 
using summary statistics from rare-variant association studies. 
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FIGURE LEGENDS 
Figure 1:  (A) Tileplot of Spearman correlation coefficients between p-values derived from the true 
kernel test statistic (i.e., SKAT or SKAT-O applied to   ) with the p-values from the Stouffer 
combined Z approach based on gene-level p-values.  Tiles are colored by degree of correlation as 
indicated by the key, with correlation estimates included in the tiles.  Adjacent columns corresponding 
to a particular analysis configuration (indicated by brackets on top of the figure) are for          
(left) and         (right).  (B)  Example scatterplots for –log10 transformed p-values 
corresponding to the true kernel gene-set analysis test (x-axis) and the Stouffer combined Z p-value 
(y-axis) for gene-set    under      . 
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Figure 2:  Visualization of expected and example observed correlation structures from the gene-set 
rare-variant association simulation study.  Correlation matrices corresponding to (from left to right) 
the design matrix  for the 10 Reactome gene-sets, Spearman rank correlations from the SKAT 
analysis p-values of continuous outcomes based on      , and the Spearman rank correlations 
for the Stouffer combined Z p-values under the same simulations conditions. 
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Figure 3:  Gene-set Manhattan-style plot based upon gene-level SKAT-O analysis results for (A) 
hereditary PRCA and (B) schizophrenia case-control studies.  Gene-sets for each figure are initially 
sorted by significance and then re-ordered on the basis of expected correlation structure due to 
overlapping genes as well as p-value.  The blue and red lines indicate Bonferroni-adjusted 
significance thresholds based upon the total number and effective number of gene-set tests, 
respectively, while the size of each point is a function of the total number of genes per gene-set. 
Gene-sets declared significantly associated by the latter are highlighted by gene-set name.  
 
    Gene Overlap 
Gene-Set       cMAF                                
   6 227 0.443 - 0 0 0 0 0 0 0 0 0 
   10 473 0.895 - - 0 0 3 4 0 0 0 3 
   12 634 0.790 - - - 0 0 0 0 0 0 6 
   19 868 1.386 - - - - 0 9 0 0 0 0 
   25 1255 1.888 - - - - - 8 0 0 3 15 
   27 1174 1.997 - - - - - - 0 0 3 8 
   32 1879 5.477 - - - - - - - 0 0 0 
   37 2130 3.027 - - - - - - - - 34 1 
   47 2611 4.097 - - - - - - - - - 4 
    47 2621 4.591 - - - - - - - - - - 
 
Table I:  Gene-Set properties and gene overlap for 10 randomly selected REACTOME gene-sets. 
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Pheno.   Method P-value                                
Cont. 1000 SKAT True 0.0440 0.0442 0.0416 0.0396 0.0356 0.0348 0.0258 0.0272 0.0228 0.0224 
   Stouffer 0.0518 0.0526 0.0498 0.0484 0.0536 0.0542 0.0512 0.0474 0.0530 0.0472 
 2000 SKAT True 0.0466 0.0474 0.0444 0.0412 0.0422 0.0396 0.0352 0.0334 0.0312 0.0352 
   Stouffer 0.0452 0.0464 0.0486 0.0514 0.0550 0.0502 0.0494 0.0462 0.0446 0.0558 
 1000 SKAT-O True 0.0536 0.0494 0.0502 0.0448 0.0490 0.0404 0.0362 0.0396 0.0392 0.0318 
   Stouffer 0.0546 0.0510 0.0462 0.0446 0.0382 0.0368 0.0396 0.0376 0.0348 0.0346 
 2000 SKAT-O True 0.0494 0.0530 0.0464 0.0458 0.0508 0.0446 0.0430 0.0414 0.0372 0.0430 
   Stouffer 0.0444 0.0480 0.0436 0.0450 0.0462 0.0392 0.0434 0.0354 0.0332 0.0382 
Binary 1000 SKAT True 0.0626 0.0512 0.0548 0.0526 0.0528 0.0566 0.0484 0.0586 0.0574 0.0566 
   Stouffer 0.0594 0.0518 0.0572 0.0504 0.0500 0.0564 0.0494 0.0552 0.0556 0.0520 
 2000 SKAT True 0.0472 0.0448 0.0444 0.0416 0.0392 0.0432 0.0348 0.0374 0.0366 0.0360 
   Stouffer 0.0492 0.0468 0.0510 0.0536 0.0530 0.0558 0.0496 0.0520 0.0584 0.0632 
 1000 SKAT-O True 0.0622 0.0534 0.0558 0.0536 0.0442 0.0534 0.0482 0.0504 0.0482 0.0560 
   Stouffer 0.0522 0.0500 0.0552 0.0556 0.0512 0.0558 0.0454 0.0532 0.0532 0.0530 
 2000 SKAT-O True 0.0494 0.0440 0.0458 0.0520 0.0428 0.0474 0.0456 0.0466 0.0412 0.0428 
   Stouffer 0.0480 0.0450 0.0432 0.0448 0.0422 0.0366 0.0364 0.0402 0.0340 0.0348 
Table II:  Empirical false positive rates for the direct application of SKAT/SKAT-O (i.e., “True”) and Stouffer combined Z gene-set p-values from the null 
simulation study based upon an alpha level of 0.05.  Error rates significantly different from the expectation of 0.05 based upon a Bonferroni-adjusted (160 
tests) two-sided binomial test are highlighted in bold. 
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Analysis 
Number of Gene-Sets Number of 
Unique Genes 
FWER by Correction Factor 
(      ) 
         
        
             
        
    
   673 368.7 500 5637 0.0416 0.0731 0.0550 
   2109 1084.2 1515 9701 0.0398 0.0727 0.0537 
   6124 3885.1 4966 17272 0.0418 0.0674 0.0511 
Table III:  Gene-set analysis summaries and empirical FWER results by Bonferroni correction factor 
using the total number of gene-set test   as well as two effective test number estimates,     
    and 
       
   .  FWERs significantly different from the expectation of 0.05 based upon a Bonferroni-
adjusted (9 tests) two-sided binomial test are highlighted in bold. 
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Effect  
Direction 
Causal  
Gene % 
 Continuous Outcome  Binary Outcome 
  Gene-set SKAT-O aSPUpath gsSKAT  SKAT-O aSPUpath gsSKAT 
One-way 100    0.570 0.487 0.450  0.635 0.492 0.480 
     0.581 0.463 0.453  0.664 0.458 0.478 
     0.825 0.666 0.608  0.903 0.715 0.725 
     0.991 0.971 0.915  0.984 0.960 0.939 
      0.972 0.898 0.889  0.993 0.917 0.927 
          
 50    0.275 0.285 0.218  0.305 0.257 0.257 
     0.298 0.267 0.209  0.282 0.204 0.221 
     0.486 0.385 0.359  0.521 0.385 0.401 
     0.712 0.742 0.600  0.764 0.707 0.658 
      0.674 0.596 0.542  0.755 0.595 0.628 
          
 25    0.138 0.161 0.118  0.091 0.119 0.088 
     0.171 0.190 0.128  0.138 0.127 0.145 
     0.194 0.226 0.176  0.215 0.213 0.180 
     0.328 0.479 0.293  0.316 0.364 0.309 
      0.280 0.362 0.239  0.356 0.315 0.312 
          
Mixed 100    0.529 0.473 0.447  0.403 0.349 0.359 
     0.526 0.457 0.447  0.401 0.315 0.332 
     0.752 0.627 0.608  0.638 0.492 0.561 
     0.955 0.957 0.915  0.924 0.883 0.872 
      0.937 0.882 0.889  0.899 0.775 0.871 
          
 50    0.274 0.266 0.229  0.216 0.212 0.175 
     0.261 0.250 0.206  0.176 0.191 0.171 
     0.418 0.380 0.339  0.314 0.257 0.298 
     0.630 0.733 0.547  0.533 0.545 0.518 
      0.601 0.607 0.559  0.469 0.418 0.492 
          
 25    0.131 0.164 0.122  0.091 0.105 0.082 
     0.158 0.167 0.148  0.113 0.109 0.106 
     0.192 0.210 0.158  0.144 0.148 0.150 
     0.299 0.464 0.316  0.193 0.267 0.227 
      0.217 0.342 0.234  0.189 0.238 0.257 
 
Table IV:  Power simulation results for binary and continuous outcomes for analysis conditions 
defined by effect direction (one-way or randomly mixed), causal gene percentage (100%, 50%, or 
25%), and gene-set.  Empirical power estimates are derived at the   level of 0.05, with highest level 
per scenario highlighted in bold. 
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  Continuous Binary 
Analysis Corr. Factor N = 500 N = 1000 Min N (     ) N = 2000 N = 4000 Min N (     ) 
     0.214 0.666 1345 0.356 0.789 4118 
     
    0.229 0.680 1320 0.373 0.799 4014 
     0.165 0.614 1427 0.295 0.749 4458 
     
    0.178 0.629 1405 0.311 0.760 4367 
     0.129 0.566 1491 0.245 0.711 4781 
     
    0.136 0.575 1480 0.254 0.719 4721 
 
Table V:  Estimates of statistical power and minimum sample size to achieve 80% power for gene-set    under a variety of sample size and total gene-set 
conditions.  Results are presented at alpha levels defined by Bonferroni correction using total number of gene-sets   per analysis   ,  , and   , as well as 
corresponding estimate of effective number of tests     
   . 
 
